Health Supervision for Children With Neurofibromatosis Type 1
- PMID: 31010905
- DOI: 10.1542/peds.2019-0660
Health Supervision for Children With Neurofibromatosis Type 1
Abstract
Neurofibromatosis type 1 (NF1) is a multisystem disorder that primarily involves the skin and peripheral nervous system. Its population prevalence is approximately 1 in 3000. The condition is usually recognized in early childhood, when pigmentary manifestations emerge. Although NF1 is associated with marked clinical variability, most children affected follow patterns of growth and development within the normal range. Some features of NF1 can be present at birth, but most manifestations emerge with age, necessitating periodic monitoring to address ongoing health and developmental needs and minimize the risk of serious medical complications. In this report, we provide a review of the clinical criteria needed to establish a diagnosis, the inheritance pattern of NF1, its major clinical and developmental manifestations, and guidelines for monitoring and providing intervention to maximize the health and quality of life of a child affected.
Copyright © 2019 by the American Academy of Pediatrics.
Conflict of interest statement
POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose.
Similar articles
-
Health supervision for children with neurofibromatosis.Pediatrics. 2008 Mar;121(3):633-42. doi: 10.1542/peds.2007-3364. Pediatrics. 2008. PMID: 18310216 Review.
-
Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 1.Clin Cancer Res. 2017 Jun 15;23(12):e46-e53. doi: 10.1158/1078-0432.CCR-17-0589. Clin Cancer Res. 2017. PMID: 28620004 Review.
-
[Neurofibromatosis type 1 or Von Recklinghausen's disease].Rev Med Interne. 2005 Mar;26(3):196-215. doi: 10.1016/j.revmed.2004.06.011. Rev Med Interne. 2005. PMID: 15777582 Review. French.
-
Psychosocial Features of Neurofibromatosis Type 1 in Children and Adolescents.J Child Neurol. 2018 Mar;33(3):225-232. doi: 10.1177/0883073817749367. Epub 2018 Jan 10. J Child Neurol. 2018. PMID: 29318935 Review.
-
[Care recommendations for type 1 neurofibromatosis].Acta Biomed Ateneo Parmense. 2000;71(3-4):83-7. Acta Biomed Ateneo Parmense. 2000. PMID: 11424620 Italian.
Cited by
-
Phakomatoses and Endocrine Gland Tumors: Noteworthy and (Not so) Rare Associations.Front Endocrinol (Lausanne). 2021 May 6;12:678869. doi: 10.3389/fendo.2021.678869. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34025587 Free PMC article. Review.
-
[Progress in diagnosis and treatment of neurofibromatosis in children].Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2022 Jun;36(6):477-482. doi: 10.13201/j.issn.2096-7993.2022.06.015. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2022. PMID: 35822370 Free PMC article. Review. Chinese.
-
A Child Plexiform Neurofibroma of the Temple Region: A Case Report.Cureus. 2024 May 21;16(5):e60798. doi: 10.7759/cureus.60798. eCollection 2024 May. Cureus. 2024. PMID: 38903359 Free PMC article.
-
Update on Pediatric Cancer Surveillance Recommendations for Patients with Neurofibromatosis Type 1, Noonan Syndrome, CBL Syndrome, Costello Syndrome, and Related RASopathies.Clin Cancer Res. 2024 Nov 1;30(21):4834-4843. doi: 10.1158/1078-0432.CCR-24-1611. Clin Cancer Res. 2024. PMID: 39196581 Free PMC article. Review.
-
Early detection of malignant and pre-malignant peripheral nerve tumors using cell-free DNA fragmentomics.medRxiv [Preprint]. 2024 Mar 11:2024.01.18.24301053. doi: 10.1101/2024.01.18.24301053. medRxiv. 2024. Update in: Clin Cancer Res. 2024 Oct 1;30(19):4363-4376. doi: 10.1158/1078-0432.CCR-24-0797. PMID: 38293154 Free PMC article. Updated. Preprint.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous